RJFSA
CTMX icon

Raymond James Financial Services Advisors’s CytomX Therapeutics CTMX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,227
Closed -$44K – 3350
2021
Q4 		$44K Buy
+10,227
New +$59.9K ﹤0.01% 3201
2021
Q3 		– Sell
-22,840
Closed -$145K – 3317
2021
Q2 		$145K Buy
22,840
+5,000
+28% +$38.9K ﹤0.01% 3085
2021
Q1 		$138K Buy
+17,840
New +$141K ﹤0.01% 2998

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Raymond James Financial Services Advisors's CTMX Position: Q1 2022 in Review

Raymond James Financial Services Advisors sold out of CytomX Therapeutics (CTMX) in Q1 2022, closing a stake of 10,227 shares — an estimated $44K sold.

Raymond James Financial Services Advisors first reported a position in CTMX in Q1 2021 and held it in 3 quarters. The position peaked at $145K in Q2 2021. 119 funds tracked by Wall St. Rank hold CTMX as of Q1 2022.

  • Raymond James Financial Services Advisors reported no remaining CytomX Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 10,227 CytomX Therapeutics shares in Q1 2022, an estimated $44K.
  • Raymond James Financial Services Advisors first reported a position in CytomX Therapeutics in Q1 2021 and held it in 3 quarters.
  • Raymond James Financial Services Advisors's CytomX Therapeutics position peaked at $145K in Q2 2021.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2022, filed 11 May 2022.